PHARMACEUTICALS
Figure 2 – Top C ( D ) MOs by COVID-19 contract service agreements Source – GlobalData . Fujifilm has mixed excess capacity and dedicated contract business models because contracts are signed with different segments of the company
‣ company has one contract each for Moderna ’ s , AstraZeneca ’ s and J & J ’ s vaccines . Lonza ’ s contracts include a ten-year API manufacturing contract with Moderna , which was signed in May 2020 , and for which it is building commercial production lines in the US , Switzerland and the Netherlands . Emergent has been one of the largest winners from the contract manufacturing of COVID-19 vaccines and therapies , but that is poised to change following disasters at its plant at Baltimore , where up to 30 million doses of vaccine were ruined . An FDA inspection found cross-contamination between AstraZeneca ’ s and J & J ’ s vaccines , as well as problems in the facility with cleanliness and overcrowding with materials .
In addition to performing contract manufacturing , Emergent markets and develops products for public health threats , including infectious diseases and chemical weapons . In June 2020 , the company invested $ 75 million in viral vector and gene therapy production up to 1,000-litres scale at its site in Canton , Massachusetts . It has nine manufacturing sites in total . Most CMOs with contracts for COVID-19 vaccines and therapies are privately owned . This reflects the general make-up of the dedicated CMO industry , as more than 90 % of dedicated CMOs are privately owned , although several of the largest are public . Private equity firms now own many of the world ’ s leading CMOs , such as Recipharm , Cambrex and PCI Pharma Services . Private CMOs are more likely to have vaccine contracts than therapies , but no single one dominates as 120 different private CMOs have COVID-19 contracts . •
References :
1 : COVID-19 : Contract Pharmaceutical Development & Manufacturing Relationships , GlobalData Report , September 2021
2 : BIO 2021 : mRNA Vaccine Booster Shots for COVID-19 and Increasing Uptake Will Offer CMOs Lucrative Opportunities , Bio / Pharmaceutical Outsourcing Report , GlobalData , July 2021
3 : FDA OKs Third Dose for Pfizer and Moderna COVID-19 Vaccines : What Does It Mean for Manufacturing ?, Bio / Pharmaceutical Outsourcing Report , GlobalData , August 2021
22 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981